Mankind Pharma to Acquire 70% Stake in Belgian Biotech Firm ACTx for 48 Million Euros
Mankind Pharma announced plans to acquire a 70% stake in Belgium-based biotech firm Armed Cell Therapeutics (ACTx) for 48 million euros, marking its entry into next-generation CAR-T cancer therapies. The acquisition, via its Netherlands subsidiary, provides access to advanced cell-therapy research targeting non-Hodgkin lymphoma and small-cell lung cancer. This move expands Mankind's global innovation focus beyond its predominantly India-centric pharmaceutical business and strengthens its presence in European biotechnology research.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 40/100.
Outlets measured: moneycontrol, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 15 Oct, 02:47 pm. Other outlets followed.